Welcome to our dedicated page for Immatics N.V news (Ticker: IMTX), a resource for investors and traders seeking the latest updates and insights on Immatics N.V stock.
Immatics N.V. develops clinical-stage cancer immunotherapies built around T-cell receptor biology, with a stated focus on precision targeting of PRAME across solid tumors. News about IMTX most often covers clinical updates for PRAME-directed cell therapies and TCR bispecifics, including anzu-cel (anzutresgene autoleucel, IMA203), IMA203CD8, IMA402 and IMA401 MAGEA4/8. Company announcements also cover presentations at oncology meetings such as ASCO, AACR and ESMO, where Immatics reports safety, dose-escalation and anti-tumor activity data across melanoma, ovarian cancer, synovial sarcoma and other PRAME-positive cancers.
Recurring updates include financial results, business updates, collaboration activity, clinical and regulatory disclosures, leadership changes, shareholder voting matters and capital-structure disclosures for the Nasdaq-listed biotechnology company.
Immatics N.V. (NASDAQ: IMTX) has announced an update on its IMA204 ACTengine® cell therapy program targeting the COL6A3 exon 6 tumor antigen, prevalent in various solid cancers. The company is progressing towards submitting an IND application to the FDA in 2021. Preclinical studies have shown two affinity-enhanced TCR candidates demonstrating high specificity and potency, with one candidate engaging both CD8+ and CD4+ T cells. IMA204 aims to effectively address the complex tumor microenvironment, providing a new approach for treating solid tumors.
Immatics N.V. (NASDAQ: IMTX) reported significant milestones following its merger with ARYA Life Science Acquisition Corp., which raised $253 million in July 2020. The company has $322 million in cash and equivalents, ensuring capital for at least 36 months. Clinical programs have expanded to Europe, with first patient treated for IMA202 and regulatory approval for IMA203. The leadership team was enhanced with the appointment of a new Chief Medical Officer. Q2 2020 revenue rose to €6.9 million, but the net loss increased to €21.3 million due to elevated R&D and G&A expenses.
Immatics N.V. (NASDAQ: IMTX) has announced the successful treatment of the first patient in the IMA202-101 clinical trial in Germany, following approval from the Paul-Ehrlich-Institute (PEI). The PEI also approved a new phase I clinical trial for the IMA203 product candidate. Moreover, three sites in Germany are actively recruiting for the IMA200 trial series, aiming to develop T cell therapies targeting cancer. These trials focus on safety, tolerability, and initial efficacy indications. Immatics is expanding its clinical footprint to enhance patient access to innovative immunotherapy options.
Immatics N.V. (NASDAQ: IMTX) announced an extension of its collaboration with UTHealth until the end of 2024. This partnership ensures Immatics exclusive access to advanced cGMP manufacturing facilities, crucial for their Adoptive Cell Therapy (ACT) clinical trials across the US and Europe. The facility can produce up to 48 ACTengine® T cell products monthly. Immatics expects this collaboration will support its early-stage clinical programs and enhance its manufacturing capabilities, as highlighted by executives from both organizations.
Immatics N.V. (NASDAQ: IMTX) announced significant changes to its Board of Directors following its recent NASDAQ listing. New members include Michael Atieh, Paul Carter, Heather Mason, and Adam Stone, who will contribute diverse expertise to advance the company's innovative T cell receptor (TCR)-based cancer therapies. Chairman Peter Chambré emphasized the importance of these developments for enhancing shareholder value and improving patient outcomes.
Immatics N.V. has successfully completed its business combination with Arya Sciences Acquisition Corp. on July 1, 2020. The newly formed entity will trade under the ticker symbols 'IMTX' for common stock and 'IMTXW' for warrants on the Nasdaq Capital Market. The deal generated approximately $253 million in proceeds, combining funds from Arya's trust account and PIPE financing from notable healthcare institutional investors. Immatics aims to leverage this capital to advance its cancer immunotherapy programs targeting solid tumors.